Evolus, Inc. (NASDAQ:EOLS)
| Market Cap | 498.85M+21.9% |
| Revenue (ttm) | 316.49M+13.9% |
| Net Income | -34.33M+44.6% |
| EPS | -0.52+47.1% |
| Shares Out | 65.85M |
| PE Ratio | n/a |
| Forward PE | 29.71 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 271,309 |
| Open | 7.68 |
| Previous Close | 7.74 |
| Day's Range | 7.54 - 7.68 |
| 52-Week Range | 3.86 - 9.31 |
| Beta | 1.34 |
| Analysts | Buy |
| Price Target | 18.40(+142.90%) |
| Earnings Date | Nov 4, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About EOLS
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$EOLS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in EOLS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by EOLS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
EOLS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
EOLS Revenue by Segment or Geography
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New EOLS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to EOLS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in EOLS
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $14.04M |
| IWMiShares Russell 2000 ETF | $12.14M |
| VXFVanguard Extended Market ETF | $6.97M |
| IWOiShares Russell 2000 Growth ETF | $4.22M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $3.35M |
| VTWOVanguard Russell 2000 ETF | $3.10M |
Estimated from each fund’s disclosed top holdings × AUM
EOLS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from EOLS’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score